F179 The influence of postmenopausal oestradiol-dydrogesterone therapy on blood pressure

Mooren, MJ van der

doi:10.1016/s0378-5122(97)81140-1

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 6 months of treatment, a slight but significant fall of systolic and diastolic BP was registered for the entire pooled group. After 1 year, however, the group receiving 10 mg of DYD showed a significant rise (about 2–3 mmHg) of both systolic and diastolic BP 91. In another study, DYD in doses ranging between 5 and 20 mg per day, combined with 1 or 2 mg of E2, appeared to be particularly neutral in terms of both metabolic and vascular effects 92…”

Section: Ht In Normotensive Womenmentioning

confidence: 95%

“…On the other hand, the administration of oral E2 plus DYD caused an increase of 6.8 and 8.6 mmHg of systolic and diastolic BP, respectively, in a group of 99 hypertensive women. 91 Fourteen postmenopausal women with grade 1–2 hypertension were enrolled in a double blind crossover study. There were four randomized treatment phases, each lasting 4 weeks: CEE 0.3 mg, CEE 0.625 mg, CEE 1.25 mg and placebo.…”

Section: Hypertensive Womenmentioning

confidence: 99%

See 1 more Smart Citation

Modification of blood pressure in postmenopausal women: role of hormone replacement therapy

Cannoletta¹,

Cagnacci²

2014

IJWH

View full text Add to dashboard Cite

The rate of hypertension increases after menopause. Whether estrogen and progesterone deficiency associated with menopause play a role in determining a worst blood pressure (BP) control is still controversial. Also, studies dealing with the administration of estrogens or hormone therapy (HT) have reported conflicting evidence. In general it seems that, despite some negative data on subgroups of later postmenopausal women obtained with oral estrogens, in particular conjugated equine estrogens (CEE), most of the data indicate neutral or beneficial effects of estrogen or HT administration on BP control of both normotensive and hypertensive women. Data obtained with ambulatory BP monitoring and with transdermal estrogens are more convincing and concordant in defining positive effect on BP control of both normotensive and hypertensive postmenopausal women. Overall progestin adjunct does not hamper the effect of estrogens. Among progestins, drospirenone, a spironolactone-derived molecule, appears to be the molecule with the best antihypertensive properties.

show abstract

Section: Ht In Normotensive Womenmentioning

confidence: 95%

Section: Hypertensive Womenmentioning

confidence: 99%